Story perspectives

Court of Appeal Dismisses Appeals, Upholds £240m Hydrocortisone Penalties

7/28/2026

Summary

Story summary

UK Court of Appeal dismissed Auden Mckenzie Limited and Actavis Limited’s appeals, upholding CMA’s finding of hydrocortisone pricing abuse and anti-competitive agreements.
The Court sent the appeals to the Competition Appeal Tribunal, where CMA penalties total £240 million after a £26 million reduction.
Auden Mckenzie, which bought the licences in 2008 and raised prices from under £1 to £70 by 2016, faces a £2.8 million penalty and a January 2027 trial over 10 mg agreements.

1 of 1

Story summary

UK Court of Appeal dismissed Auden Mckenzie Limited and Actavis Limited’s appeals, upholding CMA’s finding of hydrocortisone pricing abuse and anti-competitive agreements.
The Court sent the appeals to the Competition Appeal Tribunal, where CMA penalties total £240 million after a £26 million reduction.
Auden Mckenzie, which bought the licences in 2008 and raised prices from under £1 to £70 by 2016, faces a £2.8 million penalty and a January 2027 trial over 10 mg agreements.